Cargando…
The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naïve and pre-treated but protease inhibitor (PI)- naïve hiv-infected patients
OBJECTIVE: We have previously reported data from the German cohort of the multinational observational prospective RAINBOW survey which assessed the tolerability and efficacy of ritonavir-boosted saquinavir (SQV/r)-containing regimens over 48 weeks in routine clinical practice. This analysis presents...
Autores principales: | Knechten, H, Stephan, C, Mosthaf, FA, Jaeger, H, Carganico, A, Lutz, T, Schewe, K, Mayr, C, Wolf, E, Wellmann, E, Tappe, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352211/ https://www.ncbi.nlm.nih.gov/pubmed/21486721 http://dx.doi.org/10.1186/2047-783X-16-3-93 |
Ejemplares similares
-
Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients
por: Stephan, C, et al.
Publicado: (2010) -
Safety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir Mesylate
por: Knechten, Heribert, et al.
Publicado: (2010) -
Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, HIV-Infected Patients
por: Julio, Montaner SG, et al.
Publicado: (2006) -
The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
por: Wiesmann, Frank, et al.
Publicado: (2011) -
Insights into antiretroviral treatment changes in previously naïve patients: results of a Portuguese cohort
por: Silva, C, et al.
Publicado: (2010)